Mr. Sean Egan:

I met my counterpart in the context of medical device regulation approximately two months ago. That was a more general discussion around planning for challenges we would collectively need to manage in the context of artificial intelligence. Clearly, a lot of artificial intelligence products are products that will need to be regulated. As with any technology there is also a requirement to ensure it is applied safely in practice. It was a planning meeting to open up early discussions on how we will collectively address this issue that we know we will both need to manage in the future.